No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
BDSX Biodesix
- 1.600
- +0.020+1.27%
Close Jul 3 13:00 ET
- 1.590
- -0.010-0.63%
Post 15:18 ET
183.50MMarket Cap-2962P/E (TTM)
1.630High1.570Low61.61KVolume1.610Open1.580Pre Close99.02KTurnover0.18%Turnover RatioLossP/E (Static)114.69MShares2.21052wk High-33.33P/B54.62MFloat Cap1.03052wk Low--Dividend TTM34.14MShs Float31.990Historical High--Div YieldTTM3.80%Amplitude0.955Historical Low1.607Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Biodesix Named to Inc. Magazine's 2024 "Best Workplaces"
Awarding Excellence in Company Culture Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company, is honored to announce it has been named to Inc. Magazine's Best Workplaces list. The ranking is a result of
Biodesix to Participate in Two Investor Conferences in June
Biodesix, Inc. (NASDAQ:BDSX), a leading diagnostic solutions company with a focus in lung disease, today announced Scott Hutton, Chief Executive Officer, will participate in two upcoming investor conferences: William
Biodesix to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting
Data highlights ability of the Nodify XL2 test to identify benign nodules in patients with emphysema.
Biodesix Initiated at Buy by TD Cowen
Biodesix Initiated at Buy by TD Cowen
Biodesix Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/13/2024 68.67% TD Cowen → $2.8 Initiates Coverage On → Buy 05/03/2024 80.72% Lake Street → $3 Initiates
Buy Rating Justified by Biodesix's Market Leadership and Strong Growth Prospects
Comments
$Biodesix(BDSX.US$ buy ✈️💰💰💰
1
1
$Biodesix(BDSX.US$ TEST CAN NOT SHORT MUST NOT BUY 🔊📢👹
Gainers:
In reaction to earnings/guidance:
• $Omnicom Group(OMC.US$ +6.8% (Omnicom reports Q2 EPS $1.68, consensus $1.58)
• $Netflix(NFLX.US$+6.3% (Netflix executives said they expect 1 million new subscribers to join in the third quarter, with revenue forecast to grow to $7.84 billion from $7.48 billion a year ago)
• $Fulton Financial(FULT.US$ +4.3% (Fulton Financial reports Q2 EPS 42c, consensus 37c)
• $Abbott Laboratories(ABT.US$ +0.6% (Ab...
In reaction to earnings/guidance:
• $Omnicom Group(OMC.US$ +6.8% (Omnicom reports Q2 EPS $1.68, consensus $1.58)
• $Netflix(NFLX.US$+6.3% (Netflix executives said they expect 1 million new subscribers to join in the third quarter, with revenue forecast to grow to $7.84 billion from $7.48 billion a year ago)
• $Fulton Financial(FULT.US$ +4.3% (Fulton Financial reports Q2 EPS 42c, consensus 37c)
• $Abbott Laboratories(ABT.US$ +0.6% (Ab...
19
2
$Biodesix(BDSX.US$
small float on market watch, is this a squeeze play? The chart has a lot of promise
small float on market watch, is this a squeeze play? The chart has a lot of promise
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
104533867since2024 : hi what's the target?